Description:

Age Related Macular Degeneration (AMD) has become near epidemic levels and continues to be a leading cause of legal blindness globally.  With advances in intravitreal treatment, it has become very important to identify cases of neovascular (wet) AMD early rather than late.  Despite improvement in technology many AMD patients still arrive late to the retina clinic after significant loss of visual function. Clinicians can do better!  This course will outline a comprehensive review of current imaging options available and the variations in AMD presentation with SDOCT technology, autofluorescence and OCT angiography. In addition the landscape for treatment of neovascular (wet) AMD is ever changing and this course will provide a current update on the many intravitreal and surgical options currently available for the management of neovascular AMD.  In addition, if you want to prevent visual loss from advanced AMD you must first prevent advanced AMD. This course will summarize current micronutrient supplements that should be recommended to our patients.

Course Code:

AOA359-TD

Speaker(s):

Jay Haynie, O.D.

drjay@soundretina.com

Mohammad Rafieetary, O.D.

mrafieetary@charlesretina.com

Credits:

2

AOA Expiration Date:

12/15/2025

Related News

‘Profits over patients cannot continue’ with VBMs; Texas testifies at health insurance hearing

As Texas defends its landmark law curbing vision benefit managers (VBMs), doctors of optometry testify at a hearing on the state’s health insurance market.

Kentucky attorney general holds Warby Parker accountable for its online vision test

Enduring advocacy by the Kentucky Optometric Association regarding retailer’s online eye test shows results as its state attorney general reaches settlement with Warby Parker that results in a fine announced May 10.

Next-gen optometry’s focus on independent practice

Preparing optometry students for practice autonomy is an imperative the AOA doesn’t take lightly, doubling down with partnering academic institutions for the profession’s future.